ReviewGut microbes2014
The potential for emerging therapeutic options for Clostridium difficile infection.
Review in Gut microbes, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Synthetic PS-III Glycoconjugate Vaccines Based on Solid-Phase Assembled Well-Defined Oligosaccharides Confers Protection againstACS central science · 2026Article
- Establishing and analyzing the Simplified Human Intestinal Microbiota (SIHUMI) as a versatile in vitro gut microbiome model with qPCR-based strain-level tracking.Nature protocols · 2026Review
- Synergistic and off-target effects of bacteriocins in a simplified human intestinal microbiome: implications forGut microbes · 2025Article
- Encapsulation protocol for fecal microbiota transplantation.Frontiers in cellular and infection microbiology · 2024Article
- Rifaximin Therapy for Patients With Metronidazole-Unresponsive Clostridium difficile Infection.Cureus · 2022Article
- Bacteriocins: Properties and potential use as antimicrobials.Journal of clinical laboratory analysis · 2022Review
- Article
- Bacteriocins From LAB and Other Alternative Approaches for the Control ofFrontiers in bioengineering and biotechnology · 2020Review
- Recent advances in the treatment ofInfection and drug resistance · 2019Article
- Advances in the diagnosis and treatment of Clostridium difficile infections.Emerging microbes & infections · 2018Review
- Article
- Review
- Novel Antimicrobials for the Treatment ofFrontiers in medicine · 2018Review
- Control ofMicrobiology spectrum · 2017Review
- Advances in the Microbiome: Applications to Clostridium difficile Infection.Journal of clinical medicine · 2016Review
- Biochemical Properties and Mechanism of Action of Enterocin LD3 Purified from Enterococcus hirae LD3.Probiotics and antimicrobial proteins · 2016Article
- Screening of Bifidobacteria and Lactobacilli Able to Antagonize the Cytotoxic Effect of Clostridium difficile upon Intestinal Epithelial HT29 Monolayer.Frontiers in microbiology · 2016Article
- An update on antibody-based immunotherapies for Clostridium difficile infection.Clinical and experimental gastroenterology · 2016Review
- Length of Hospital Stay and Bed Occupancy Rates in Former Yugoslav Republics 1989-2015.Frontiers in pharmacology · 2016Article
- Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis.International journal of general medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium difficile is mainly a nosocomial pathogen and is a significant cause of antibiotic-associated diarrhea. It is also implicated in the majority of cases of pseudomembranous colitis. Recently, advancements in next generation sequencing technology (NGS) have highlighted the extent of damage to the gut microbiota caused by broad-spectrum antibiotics, often resulting in C. difficile infection (CDI). Currently the treatment of choice for CDI involves the use of metronidazole and vancomycin. However, recurrence and relapse of CDI, even after rounds of metronidazole/vancomycin administration is a problem that must be addressed. The efficacy of alternative antibiotics such as fidaxomicin, rifaximin, nitazoxanide, ramoplanin and tigecycline, as well as faecal microbiota transplantation has been assessed and some have yielded positive outcomes against C. difficile. Some bacteriocins have also shown promising effects against C. difficile in recent years. In light of this, the potential for emerging treatment options and efficacy of anti-C. difficile vaccines are discussed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.